FF-10502 is an anti-metabolite with novel activity on dormant cells. FF-10502 acts superior to gemcitabine for targeting pancreatic cancer cells. References: Mima S, Kakinuma C, Higuchi T, Saeki K, Yamada T, Uematsu R, Ishino M, Kito N, Nishikawa H, Kuniyoshi H, Matsumoto T, Fujiwara H, Paradiso LJ, Shimada Y, Iwamura H. FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. doi: 10.1124/jpet.118.248740. Epub 2018 Apr 13. PubMed PMID: 29653962.

纯度：≥98%

CAS：184302-49-6